Sanofi $SNY Shares Sold by Redwood Grove Capital LLC

Redwood Grove Capital LLC trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 56.8% during the 1st quarter, HoldingsChannel.com reports. The firm owned 81,557 shares of the company’s stock after selling 107,284 shares during the quarter. Sanofi makes up 1.3% of Redwood Grove Capital LLC’s investment portfolio, making the stock its 20th largest position. Redwood Grove Capital LLC’s holdings in Sanofi were worth $3,929,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi during the 4th quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its stake in Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after buying an additional 379 shares in the last quarter. Leonteq Securities AG boosted its holdings in Sanofi by 95.8% in the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after buying an additional 297 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi in the 3rd quarter worth about $29,000. Finally, Palisade Asset Management LLC purchased a new stake in Sanofi during the 3rd quarter worth approximately $30,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Stock Up 3.5%

Shares of NASDAQ SNY opened at $45.54 on Wednesday. The stock has a market cap of $110.41 billion, a PE ratio of 12.72, a P/E/G ratio of 1.12 and a beta of 0.34. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The company has a 50-day moving average of $43.49 and a 200 day moving average of $45.29.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SNY. Argus upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a research report on Monday, April 20th. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, Morgan Stanley set a $49.00 price objective on Sanofi in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $49.50.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.